Safety Study of TroVax Alone vs. TroVax Plus Interferon Alpha in Patients With Renal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

January 31, 2008

Study Completion Date

February 29, 2008

Conditions
Carcinoma, Renal Cell
Interventions
BIOLOGICAL

TroVax® (Immunological Vaccine Therapy)

16 Intramuscular injections of TroVax® over 47 weeks

DRUG

Interferon-alpha

36 subcutaneous IFN-α injections for 12 weeks. sc injection three times per week (5MU each)

Trial Locations (1)

77030

Baylor College of Medicine - Methodist Hospital, Houston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Oxford BioMedica

INDUSTRY

lead

The Methodist Hospital Research Institute

OTHER

NCT00445523 - Safety Study of TroVax Alone vs. TroVax Plus Interferon Alpha in Patients With Renal Cancer | Biotech Hunter | Biotech Hunter